411 related articles for article (PubMed ID: 8004419)
1. Validation--how much can the world afford? Are we getting value for money?
Anisfeld MH
J Pharm Sci Technol; 1994; 48(1):45-8. PubMed ID: 8004419
[TBL] [Abstract][Full Text] [Related]
2. Value for money of drug regulation.
Bouvy JC; Koopmanschap MA; Schellekens H
Expert Rev Pharmacoecon Outcomes Res; 2012 Jun; 12(3):247-9. PubMed ID: 22812545
[No Abstract] [Full Text] [Related]
3. The validation life cycle.
Agalloco J
J Parenter Sci Technol; 1993; 47(3):142-7. PubMed ID: 8360808
[TBL] [Abstract][Full Text] [Related]
4. Health care reform and the pharmaceutical industry.
Mossinghoff GJ
Health Care Manag; 1994 Aug; 1(1):187-96. PubMed ID: 10152353
[TBL] [Abstract][Full Text] [Related]
5. Impact of gatt agreement on drug prices.
Pillai AM
J Indian Med Assoc; 1995 Mar; 93(3):113, 120. PubMed ID: 8522810
[No Abstract] [Full Text] [Related]
6. US drug shortages are set to reach record high in 2011, report says.
Tanne JH
BMJ; 2011 Dec; 343():d8307. PubMed ID: 22194406
[No Abstract] [Full Text] [Related]
7. Drug shortage crisis resolution.
Duffy E
J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
[No Abstract] [Full Text] [Related]
8. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
Jimenez FA
Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
[No Abstract] [Full Text] [Related]
9. The cost of drugs.
N Z Med J; 1969 Jan; 69(440):33-4. PubMed ID: 4974999
[No Abstract] [Full Text] [Related]
10. Medical costs and the drug industry.
Schwartz H
Wall St J Midwest Ed; 1980 Apr; 60(132):22. PubMed ID: 10245744
[No Abstract] [Full Text] [Related]
11. Should the patent system for new medicines be abolished?
DiMasi JA; Grabowski HG
Clin Pharmacol Ther; 2007 Nov; 82(5):488-90. PubMed ID: 17952100
[No Abstract] [Full Text] [Related]
12. Veterinary drug availability.
Gloyd J
J Am Vet Med Assoc; 1980 Apr; 176(7):611-4. PubMed ID: 7372533
[No Abstract] [Full Text] [Related]
13. Remarks at the Food and Drug Law Institute's 48th Annual Conference.
Niedelman SM
Food Drug Law J; 2005; 60(2):117-26. PubMed ID: 16097089
[No Abstract] [Full Text] [Related]
14. Can the Food and Drug Administration ensure that our pharmaceuticals are safely manufactured?
Hubbard WK
Arch Intern Med; 2009 Oct; 169(18):1655-6. PubMed ID: 19822821
[No Abstract] [Full Text] [Related]
15. Deterring the importation of counterfeit pharmaceutical products.
Stearn DW
Food Drug Law J; 2004; 59(4):537-61. PubMed ID: 15875351
[No Abstract] [Full Text] [Related]
16. Health Canada wants more funds from pharma.
Vogel L
CMAJ; 2017 Jun; 189(24):E845-E846. PubMed ID: 28630367
[No Abstract] [Full Text] [Related]
17. Why are we Being Overcharged for Pharmaceuticals? What Should We Do About It?
Hyman DA; Silver C
J Leg Med; 2019; 39(2):137-149. PubMed ID: 31503533
[No Abstract] [Full Text] [Related]
18. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
19. Industry perspectives on ICH guidelines.
Rockhold FW
Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
[TBL] [Abstract][Full Text] [Related]
20. Your health in the 21st century. A better safety net.
Rosenberg D
Newsweek; 2005; 145(26A):70-2. PubMed ID: 16375152
[No Abstract] [Full Text] [Related]
[Next] [New Search]
